Zafirlukast


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Chronic asthma
Adult: Prophylaxis and maintenance therapy: 20 mg bid. Recommended therapeutic indications may vary between countries (refer to local or specific product guidelines).
Child: 5-11 years 10 mg bid; ≥12 years Same as adult dose. Recommended therapeutic indications may vary between countries (refer to local or specific product guidelines).
Suy gan
Contraindicated.
Cách dùng
Should be taken on an empty stomach.
Chống chỉ định
Hepatic impairment including hepatic cirrhosis.
Thận trọng
Not indicated for use in acute asthma attacks (including status asthmaticus). Children and elderly. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Hepatotoxicity (e.g. hyperbilirubinaemia, hepatitis); neuropsychiatric events (e.g. insomnia, depression); infections predominantly affecting the respiratory tract (mostly to >55 years of age). Rarely, systemic eosinophilia (sometimes manifesting with clinical features of vasculitis consistent with eosinophilic granulomatosis with polyangiitis [formerly known as Churg-Strauss syndrome]).
Blood and lymphatic system disorders: Agranulocytosis.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain, diarrhoea, dyspepsia.
General disorders and administration site conditions: Fever, oedema, malaise.
Immune system disorders: Hypersensitivity reactions (e.g. urticaria, angioedema, pruritus, rashes with or without blistering).
Investigations: Increased serum ALT.
Musculoskeletal and connective tissue disorders: Myalgia, arthralgia, back pain.
Nervous system disorders: Headache, dizziness.
Vascular disorders: Bleeding, bruising.
Potentially Fatal: Hepatic failure leading to liver transplantation.
Chỉ số theo dõi
Monitor LFTs periodically. Closely monitor for signs and symptoms of hepatic injury and neuropsychiatric symptoms or behavioural changes.
Quá liều
Symptoms: Rash and stomach upset. Management: Supportive treatment. Empty the stomach by inducing emesis or performing gastric lavage. May administer activated charcoal to prevent further absorption of unrecovered drug.
Tương tác
May enhance the anticoagulant activity of warfarin resulting in prolonged prothrombin time. May reduce serum concentration with theophylline, terfenadine, and erythromycin. Increased serum concentration with fluconazole and high doses of aspirin.
Tương tác với thức ăn
Decreased rate and extent of absorption with food.
Tác dụng
Description:
Mechanism of Action: Zafirlukast, an antiasthmatic agent, is a competitive and selective leukotriene-receptor antagonist (LTRA) of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). The production, stimulation, and receptor occupation of cysteinyl leukotriene have been correlated with the pathophysiology of asthma including smooth muscle constriction, airway oedema, and altered cellular activity related with the inflammatory process which contribute to the signs and symptoms of asthma.
Pharmacokinetics:
Absorption: Rapidly absorbed from the gastrointestinal tract. Food reduces the rate and extent of absorption. Time to peak plasma concentration: Approx 3 hours.
Distribution: Enters breast milk. Plasma protein binding: Approx 99%, mainly to albumin.
Metabolism: Extensively metabolised in the liver mainly by CYP2C9 isoenzyme into hydroxylated metabolites.
Excretion: Mainly via faeces (approx 90%, as unchanged drug and metabolites); urine (approx 10%, as metabolites). Elimination half-life: Approx 10 hours (range 8-16 hours).
Đặc tính

Chemical Structure Image
Zafirlukast

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5717, Zafirlukast. https://pubchem.ncbi.nlm.nih.gov/compound/Zafirlukast. Accessed Feb. 27, 2024.

Bảo quản
Store between 20-25°C. Protect from light and moisture.
Phân loại MIMS
Thuốc trị hen & bệnh phổi tắc nghẽn mạn tính
Phân loại ATC
R03DC01 - zafirlukast ; Belongs to the class of leukotriene receptor antagonists. Used in the systemic treatment of obstructive airway diseases.
Tài liệu tham khảo
Accolate Tablets (AstraZeneca Pharmaceuticals LP). U.S. FDA. https://www.fda.gov. Accessed 10/01/2024.

Anon. Zafirlukast. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 10/01/2024.

Anon. Zafirlukast. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/01/2024.

Buckingham R (ed). Zafirlukast. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/01/2024.

Zafirlukast Tablet, Film Coated (Aurobindo Pharma Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 10/01/2024.

Zafirlukast. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 21/02/2024.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Zafirlukast từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in